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Aurora kinases are important mitotic regulators, and Aurora kinase inhibitors are under investigation as treat-
ments for cancer. An ongoing debate in the field is which Aurora kinase is the better drug target. A new study
(Girdler et al., 2008, in this issue of Chemistry & Biology) pushes the case forward for Aurora B.Drug discovery often requires a full com-
mitment of effort while in possession of
rather less than a full understanding of
the ultimate goal. In particular, unambigu-
ous validation of a drug target is generally
difficult to achieve, and scientists from
different disciplines often have different
ideas about what constitutes useful target
modulation, a key step toward biological
validation. In part, this is because the phe-
notypes observed can depend on the
methodology used (Weiss et al., 2007).
Ultimately, practical validation of a biolog-
ical target molecule as a small-molecule
drug target requires first the identification
of a suitable small molecule and only then
a full assessment of its mode of action.
Therefore, these experiments are under-
taken fairly late in the discovery process,
sometimes even during clinical trials,
and do not always give the expected re-
sult. One might conclude that the target
and the drug must validate one another.
A new and exceptionally active target
for anticancer drug discovery is the Au-
rora kinases. There are two major human
Aurora kinases, Aurora A and Aurora B
(Carmena and Earnshaw, 2003). The in-
terest in Aurora kinases as potential ther-
apeutic targets was stimulated by the
finding that Aurora A is amplified or over-
expressed in diverse tumor types and that
transfection with Aurora A is transforming
in some cell lines (Bischoff et al., 1998).
Despite the very high sequence identity
of the Aurora A and Aurora B kinase
domains, the two proteins have distinct
mitotic functions, and each kinase is es-
sential for proper mitotic progression
and cellular viability. Aurora A localizes
predominantly to the centrosome, and
Aurora A loss of function disrupts bipolar
spindle formation. Aurora B localizes dur-
ing early mitosis first to chromosomes
and then to the inner centromere. At this
stage, Aurora B is required for spindle
assembly checkpoint (SAC) function.
Later in mitosis, Aurora B moves to the
spindle midzone, and it is required for
completion of cytokinesis.
Despite much progress toward under-
standing basic aspects of Aurora kinase
function, there are indications of an
interrelationship that is not well under-
stood. Modest overexpression of Aurora
A causes little change in the kinetics of
mitotic entry, but instead appears to inter-
fere with the SAC (Jiang et al., 2003) and
cytokinesis (Meraldi et al., 2002), both of
which depend on Aurora B function. Sim-
ilar results were obtained when two differ-
ent ‘‘kinase-dead’’ mutants of Aurora A
were overexpressed (Jiang et al., 2003;
Meraldi et al., 2002; Littlepage and Ruder-
man, 2002). In contrast, induction of ki-
nase-dead variants of Aurora A appears
to inhibit Aurora A function only in the
absence of endogenous wild-type Aurora
A (Girdler et al., 2006). Taken together,
these studies indicate that cells may
require low levels of Aurora A function to
progress through mitosis. Furthermore,
Aurora A overexpression may not pro-
duce a simple Aurora A gain of function,
but instead it may dominantly interfere
with the more sensitively balanced Aurora
B (Carmena and Earnshaw, 2003). To fur-
ther complicate matters, the transforming
activity of Aurora A does depend on cata-
lytic activity but is not further enhanced
by kinase-activating mutations (Bischoff
et al., 1998). Because some aspects of
Aurora disregulation do not require the ki-
nase activity of Aurora A, it is not obvious
that these processes can be targeted
by a small molecule, much less what the
desired selectivity profile might be.
Fortunately, potent and structurally di-
verse small molecule Aurora inhibitors
have arrived on the scene. These mole-
cules produce cellular effects indicating
Aurora A loss of function (Hoar et al.,
2007), Aurora B loss of function (Ditchfield
et al., 2003), or both (Tyler et al., 2007).
Examples from each class have been
shown to inhibit tumor growth in multiple
xenograft models and have entered
human clinical trials. Is this the end of
the story? As it happens, the story is not
so simple.
Stephen Taylor and colleagues (Girdler
et al., 2008) have taken on the question
that is so seldom asked: Does the inhibitor
really act through the intended target? It
is usually straightforward to show that a
small-molecule drug inhibits a target in
a cellular or in vivo context. However,
this does not mean that the therapeutic
benefit (e.g., tumor growth inhibition) is
caused by inhibition of this target. In the
kinase area, it is especially difficult to
demonstrate causality, as most kinase
inhibitors are far from perfectly selective
(Karaman et al., 2008). The inhibitor stud-
ied by the Taylor group (Girdler et al.,
2008) is ZM447439, originally discovered
at AstraZeneca (Ditchfield et al., 2003).
ZM447439 was observed to most closely
phenocopy Aurora B loss of function in
cellular assays, despite inhibiting Aurora
A and Aurora B in enzymatic assays.
The mechanistic connection between
Aurora B and ZM447439 was strength-
ened in a follow-up study (Girdler et al.,
2006). Tetracycline-inducible expression
of wild-type Aurora kinases or their ki-
nase-dead versions was established in
stable cell lines. Consistent with the ear-
lier studies noted here, expression of the
inactive Aurora A mutant had little effect
on cellular growth, and cells remained
capable of colony formation. In contrast,
expression of an inactive Aurora B mutant
strongly inhibited cell growth and reduced
the number of colonies. The effects on cell
number in culture and colony outgrowth
were similar to those observed upon
treatment with ZM447439. A closelyChemistry & Biology 15, June 2008 ª2008 Elsevier Ltd All rights reserved 525
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against Aurora B (and 100-fold selectivity
against Aurora A) produced all the same
phenotypic effects as ZM447439, but at
a lower concentration consistent with its
greater enzymatic potency. These results
support that ZM447439 inhibits Aurora B
(and not Aurora A) but stop short of a full
demonstration that Aurora B is the target
through which ZM447439 blocks cellular
proliferation and colony outgrowth.
The new study addresses this issue and
adds provocative questions of its own
(Girdler et al., 2008). The authors begin
by selecting for clones of HCT-116 colon
cancer cells that have acquired resistance
to ZM447439. They identify several
mutant alleles of Aurora B. They then
demonstrate that the mutant variants of
Aurora B are sufficient to confer resis-
tance to ZM447439 by establishing stable
tetracycline-inducible cell lines for each
variant. Induction of mutant Aurora B,
but not wild-type, allows colony out-
growth in the presence of ZM447439.
This establishes that Aurora B is the rele-
vant target of ZM447439 antiproliferative
activity. Even had the authors stopped at
this point, it would have been an impor-
tant contribution.
However, the authors also test the ef-
fects of two other Aurora kinase inhibitors
against the Aurora B mutant cell lines.
VX-680 (MK-0457) is an inhibitor of both
Aurora kinases in cellular assays (Tyler
et al., 2007), and MLN8054 shows selec-
tivity for Aurora A when used at 1 mM in
cellular assays (Hoar et al., 2007). The first
puzzling result is that the Aurora B muta-
tion confers resistance to VX-680 in a col-
ony outgrowth assay. This is consistent
with the known activity of VX-680 against
Aurora B. However, it also suggests that
the clearly observable inhibition of Aurora
A by VX-680 does not produce a corre-
spondingly strong antiproliferative effect.
The story becomes still more puzzling:
the ZM447439-resistant cell line remains
fully sensitive to the Aurora A-selective
inhibitor MLN8054 (Girdler et al., 2008).
What do these data imply about Aurora
A as an anticancer target? First, it is dif-
ficult to understand how inhibition of
Aurora A by two different active-site in-
hibitors could produce entirely different
results. It is possible that the cellular read-
outs for Aurora A inhibition do not reflect
full occupancy by inhibitor. Accordingly,
one possibility suggested by the authors
is that the extent of inhibition may be
less in the case of VX-680. It is well worth
comparing the two inhibitors directly in
mechanistic cellular assays to explore
this further. Amore provocative possibility
is that the antiproliferative activity of
MLN8054 is driven through a target other
than Aurora A. MLN8054 appears to be
a much more selective kinase inhibitor
than VX-680 (Karaman et al., 2008), so it
is conceivable that it has an important tar-
get that is not a kinase. Despite the strong
circumstantial evidence linking Aurora A
to cancer, it would appear that there is
still more to do before Aurora A can be526 Chemistry & Biology 15, June 2008 ª2008 Elsevier Ltd All rights reservedvalidated as definitively as Aurora B for
pharmacological intervention.
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